Biogen, Inc. (BIIB)

$300.51 3.96 (1.30%)

18:39 EDT BIIB Stock Quote Delayed 20 Minutes

Volume:

Previous Close $300.51

Market Cap 63.41B

PE Ratio 21.47

EPS 14

Volume (Avg. Vol.) 1.42M

Day's Range 296.81 - 311.53

52-Week Range 215.77 - 374.99

Dividend & Yield N/A (N/A)

BIIB Stock Predictions, Articles, and Biogen, Inc. News

From InvestorPlace
From the Web

3 Big Stock Charts for Tuesday: Biogen, Activision Blizzard, and Plug Power

By Vince Martin, InvestorPlace Contributor Mar 24, 2020

Tuesday's big stock charts feature stocks holding support whose businesses could, and maybe should, hold up in the near term.

7 Biotech Stocks to Buy and Hold in 2020

By Chris Lau, InvestorPlace Contributor Mar 16, 2020

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

3 Top Stocks You Should Watch to Invest Like Berkshire Hathaway

By Ian Cooper Feb 25, 2020

One of the best ways to profit is to invest like Warren Buffett. Here are three Berkshire Hathaway stocks that he's watching now.

Stock Market Today: New Record Highs; An $8 Trillion Opportunity

By Bret Kenwell, InvestorPlace Contributor Feb 5, 2020

Ford and Disney sank on earnings, while oil demand could shrivel up in China. Here's what happened in the stock market today.

7 Big Biotech Stocks to Avoid

By Louis Navellier, Editor, Growth Investor Jan 28, 2020

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list. Here's why.

3 Big Stock Charts for Wednesday: Biogen, Cooper Companies, and Maxim

By Vince Martin, InvestorPlace Contributor Jan 15, 2020

Wednesday's big stock charts highlight 3 stocks looking to break through resistance in a market that looks a bit shaky at the moment.

Compare Brokers

Make the Shift Toward Value Stocks With These 5 Picks

By Aaron Levitt, InvestorPlace Contributor Dec 19, 2019

Value stocks are hot these days, and the best part is the shift toward them isn't stopping anytime soon. Here are five to buy today.

5 Top Stock Trades for Friday: RH, DG, KR, BIIB

By Bret Kenwell, InvestorPlace Contributor Dec 5, 2019

RH, Dollar General, Kroger, Biogen and Signet Jewelers were our top stock trades for Friday. Let's look at the charts.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline

By Chris Lau, InvestorPlace Contributor Nov 12, 2019

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

The Good, Bad, and Ugly for Biogen Stock

By Josh Enomoto, InvestorPlace Contributor Nov 1, 2019

With news that Biogen’s Alzheimer’s drug was allowed to reapply for possible FDA approval, Biogen stock skyrocketed. However, investors will want to carefully consider all angles before jumping onboard.

Use Aimmune Therapeutics to Profit off the Rush Into Biotech

By Ken Trester, Editor, Power Options Weekly Oct 25, 2019

This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.

Wednesday’s Vital Data: Biogen, McDonald’s and Lyft

By Tyler Craig, Tales of a Technician Oct 23, 2019

Options trading was buzzing in Biogen, McDonald's and Lyft stock on Tuesday. Here are the metrics that matter moving forward.

Compare Brokers

Stock Market Today: Biogen’s Answer to Alzheimer’s

By Bret Kenwell, InvestorPlace Contributor Oct 22, 2019

Biogen erupted in early trading, as it seeks approval for its Alzheimer's treatment. Here's what happened in the stock market today.

5 Healthcare Stocks to Buy

By William Roth, InvestorPlace Market Strategist Oct 22, 2019

Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.

Stock Market Today: Stocks Rally Ahead of Big Earnings Week

By Bret Kenwell, InvestorPlace Contributor Oct 21, 2019

Another opioid settlement has been reached and earnings season is heating up. Here's what happened in the stock market today.

3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

By Louis Navellier, Editor, Growth Investor Sep 14, 2019

When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).